Socié, Gérard <br/><br/>
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.  [electronic resource] 

 -  British journal of haematology  04 2019 
 - 297-310 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/bjh.15790  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Atypical Hemolytic Uremic Syndrome--drug therapy<br/>Child<br/>Child, Preschool<br/>Complement Inactivating Agents--adverse effects<br/>Databases, Factual<br/>Fatigue--chemically induced<br/>Female<br/>Fever--chemically induced<br/>Hemoglobins--deficiency<br/>Hemoglobinuria, Paroxysmal--drug therapy<br/>Humans<br/>Infant<br/>Infant, Newborn<br/>Male<br/>Meningococcal Infections--chemically induced<br/>Middle Aged<br/>Opportunistic Infections--chemically induced<br/>Pharmacovigilance<br/>Pregnancy<br/>Pregnancy Complications--drug therapy<br/>Pregnancy Outcome<br/>Young Adult